Intravitreal Bevacizumab Treatment for Macular Edema due to Branch Retinal Vein Occlusion in a Clinical Setting

REFERENCES

• Rogers S, McIntosh RL, Cheung N et al.; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313–9e1.
   PubMed Web of Science ®Google Scholar
• Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010;8:1886–1894.
   PubMed Web of Science ®Google Scholar
• The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98:271–282.
   PubMed Web of Science ®Google Scholar
• Scott IU, Ip MS, VanVeldhuisen PC et al.; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115–1128.
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr et al.; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–1146.e3.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Channa R et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology 2010;117:2387–2394.e1.
   PubMed Web of Science ®Google Scholar
• Pece A, Isola V, Piermarocchi S et al.; Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol 2011;95:56–68.
   PubMed Web of Science ®Google Scholar
• Stahl A, Agostini H, Hansen LL et al.; Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007;245:1429–1436.
   PubMed Web of Science ®Google Scholar
• Puche N, Glacet A, Mimoun G et al.; Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. Acta Ophthalmol 2010 (Epub ahead of print).
   Google Scholar
• Rabena MD, Pieramici DJ, Castellarin AA et al.; Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina (Philadelphia, Pa) 2007;27:419–425.
   PubMed Web of Science ®Google Scholar
• Kriechbaum K, Michels S, Prager F et al.; Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518–522.
   PubMed Web of Science ®Google Scholar
• Wu L, Arevalo JF, Roca JA et al.; Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina (Philadelphia, Pa) 2008;28:212–219.
   PubMed Web of Science ®Google Scholar
• Gündüz K, Bakri SJ. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye (Lond) 2008;22:1168–1171.
   Google Scholar
• Jaissle GB, Leitritz M, Gelisken F et al.; One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27–33.
   PubMed Web of Science ®Google Scholar
• Prager F, Michels S, Kriechbaum K et al.; Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452–456.
   PubMed Web of Science ®Google Scholar
• Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica 2009;223:124–127.
   Google Scholar
• Ahmadi AA, Chuo JY, Banashkevich A et al.; The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Can J Ophthalmol 2009;44:154–159.
   PubMed Web of Science ®Google Scholar
• Gregori NZ, Rattan GH, Rosenfeld PJ et al.; Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina (Philadelphia, Pa) 2009;29:913–925.
   PubMed Web of Science ®Google Scholar
• Hoeh AE, Ach T, Schaal KB et al.; Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:1635–1641.
   PubMed Web of Science ®Google Scholar
• Ach T, Hoeh AE, Schaal KB et al.; Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:155–159.
   PubMed Web of Science ®Google Scholar
• Hoeh AE, Ruppenstein M, Ach T et al.; OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:1567–1572.
   PubMed Web of Science ®Google Scholar
• Figueroa MS, Contreras I, Noval S et al.; Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 2010;94:1052–1056.
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Szurman P, Feltgen N et al.; Retinal Vein Occlusion Study Group. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2011;249:183–192.
   PubMed Web of Science ®Google Scholar
• Lim JW. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion. Ophthalmologica 2011;225:150–154.
   PubMed Web of Science ®Google Scholar
• Cheng KC, Wu WC, Chen KJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye (Lond) 2009;23:2023–2033.
   PubMedGoogle Scholar
• Hou J, Tao Y, Jiang YR et al.; Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J 2009;122:2695–2699.
   Web of Science ®Google Scholar
• Ehrlich R, Ciulla TA, Moss AM et al.; Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol 2010;248:375–380.
   Google Scholar
• Byun YJ, Roh MI, Lee SC et al.; Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:963–971.
   Google Scholar
• Guthoff R, Meigen T, Hennemann K et al.; Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis. Ophthalmologica 2010;224:319–324.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Heier JS, Feiner L et al.; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102–1112.e1.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Schachat AP. Management of macular edema from retinal vein occlusions: you can never have too many choices. Ophthalmology 2010;117:1061–1063.
   PubMedGoogle Scholar
• Salinas-Alamán A, Zarranz-Ventura J, Caire González-Jauregui JM, et al.; Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 2011;21:434–0.
   Google Scholar
• Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK et al.; Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009;50:3432–3437.
   PubMed Web of Science ®Google Scholar
• Krebs I, Hagen S, Smretschnig E et al.; Reproducibility of segmentation error correction in age-related macular degeneration: Stratus versus Cirrus OCT. Br J Ophthalmol 2012;96:271–275.
   Google Scholar
• Chopovska Y, Jaeger M, Rambow R et al.; Comparison of central retinal thickness in healthy children and adults measured with the Heidelberg Spectralis OCT and the zeiss Stratus OCT 3. Ophthalmologica 2011;225:27–36.
   Google Scholar
• Rogers SL, McIntosh RL, Lim L et al.; Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117:1094–1101.e5.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Shah SM et al.; Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791–799.
   PubMed Web of Science ®Google Scholar
• Prasad PS, Oliver SC, Coffee RE et al.; Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. Ophthalmology 2010;117:780–784.
   PubMed Web of Science ®Google Scholar
• Funk M, Kriechbaum K, Prager F et al.; Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025–1032.
   PubMed Web of Science ®Google Scholar
• Park SP, Ahn JK. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clin Experiment Ophthalmol 2009;37:490–495.
   PubMed Web of Science ®Google Scholar
• Kaneda S, Miyazaki D, Sasaki S et al.; Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci 2011;52:2982–2988.
   PubMed Web of Science ®Google Scholar
• Russo V, Barone A, Conte E et al.; Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina (Philadelphia, Pa) 2009;29:511–515.
   PubMed Web of Science ®Google Scholar
• Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina (Philadelphia, Pa) 2011;31:1856–1862.
   PubMed Web of Science ®Google Scholar